Valeant Pharma Near Deal to Acquire Bausch & Lomb

Canada's Valeant Pharmaceuticals International is nearing a deal to acquire eye care company Bausch & Lomb from private equity owner Warburg Pincus for about $9 billion, a person familiar with the matter said on Friday.

The person requested anonymity because the matter is not public. Valeant and Bausch & Lomb could not be immediately reached for comment. Warburg Pincus declined to comment.

The Wall Street Journal, which earlier reported on the talks, said a deal might come as soon as next week.

 

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read